πŸ‡ΊπŸ‡Έ FDA
Patent

US 10675360

Targeted therapeutics

granted A61KA61K31/4196A61K31/454

Quick answer

US patent 10675360 (Targeted therapeutics) held by Madrigal Pharmaceuticals, Inc. expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Madrigal Pharmaceuticals, Inc.
Grant date
Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
1
CPC classes
A61K, A61K31/4196, A61K31/454, A61K31/4745, A61K31/496